公开(公告)号：WO2011009152A1

公开(公告)日：2011-01-27

申请号：PCT/AT2010/000271

申请日：2010-07-23

Applicant: AFFIRIS AG ,  STAFFLER, Günther ,  LÜHRS, Petra ,  MAIRHOFER, Andreas ,  MATTNER, Frank ,  SCHMIDT, Walter ,  DOLISCHKA, Andrea

Inventor： STAFFLER, Günther ,  LÜHRS, Petra ,  MAIRHOFER, Andreas ,  MATTNER, Frank ,  SCHMIDT, Walter ,  DOLISCHKA, Andrea

IPC: A61K39/00 ,  C07K7/14

CPC classification number: A61K39/385 ,  A61K39/0008 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/6081 ,  C07K14/435

Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (X 1 ) m (X 2 ) n (X 3 ) o X 4 X 5 H P X 6 (Formula I), for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X 1 is G or D; X 2 is A, P, M, G, or R; X 3 is G, A, H, or V; X 4 is S, A, D, or Y; X 5 is A, D, H, S, N, or I; X 6 is A, L or F; wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF.

Abstract translation: 包含与药学上可接受的载体结合的肽的疫苗，所述肽具有氨基酸序列（X1）m（X2）n（X3）×X4X5HPX6（式I），用于治疗和/或预防与 肾素激活的血管紧张素系统，其中X1是G或D; X2是A，P，M，G或R; X3是G，A，H或V; X4是S，A，D或Y; X5是A，D，H，S，N或I; X6是A，L或F; 其中m，n和o独立地为0或1，前提是当o为0和n为0时，当n为0时，其中肽不是DRVYIHPF。

公开(公告)号：WO2009021254A1

公开(公告)日：2009-02-19

申请号：PCT/AT2008/000281

申请日：2008-08-08

Applicant: AFFIRIS FORSCHUNGS- UND ENTWICKLUNGS GMBH ,  BRUNNER, Sylvia ,  LÜHRS, Petra ,  MATTNER, Frank ,  SCHMIDT, Walter ,  WITTMANN, Barbara

Inventor： BRUNNER, Sylvia ,  LÜHRS, Petra ,  MATTNER, Frank ,  SCHMIDT, Walter ,  WITTMANN, Barbara

IPC: A61K38/04 ,  A61P9/10

CPC classification number: C07K7/08 ,  A61K38/1709 ,  A61K39/0012 ,  A61K47/48284 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K7/06 ,  C07K16/18

Abstract: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.

Abstract translation: 本发明涉及化合物在制备用于预防和/或治疗动脉粥样硬化，动脉粥样硬化风险疾病和动脉粥样硬化后遗症的药物中的用途。